Information Provided By: 
Fly News Breaks for January 2, 2019
BMRN
Jan 2, 2019 | 07:51 EDT
As previously reported, Raymond James downgraded BioMarin to Market Perform from Outperform Analyst Laura Chico said BioMarin lacks near-term catalysts which makes it more vulnerable in a "risk off" environment. The analyst notes key valorx events do not manifest until mid-2019, and vosoritde later in the year.
News For BMRN From the Last 2 Days
BMRN
Apr 26, 2024 | 10:52 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Heron Therapeutics (HRTX),... To see the rest of the story go to thefly.com. See Story Here
BMRN
Apr 26, 2024 | 07:43 EDT
Canaccord analyst Whitney Ijem lowered the firm's price target on BioMarin to $89 from $91 and keeps a Hold rating on the shares. The firm noted investor focus remains on the bigger announcements/greater clarity that is expected at the company's September investor day rahter than the day's headline surrounding Roctavian struggles and the company's trimmed pipeline expenses.
BMRN
Apr 25, 2024 | 09:31 EDT
Scotiabank raised the firm's price target on BioMarin to $85 from $83 and keeps a Sector Perform rating on the shares following model adjustments. While the company's enzyme business remains stable, in-line Voxzogo results and a struggling Roctavian franchise has led the firm to maintain its rating on the stock.
BMRN
Apr 25, 2024 | 07:33 EDT
